Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4

🎖️ Top 10% JournalSep 3, 2025Obesity (Silver Spring, Md.)

Tirzepatide linked to better quality of life in adults with obesity or overweight

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

In a trial with 670 participants, continued tirzepatide treatment was associated with maintained health-related quality of life improvements from week 36 to week 88.

Tirzepatide treatment led to significant improvements in patient-reported outcomes from week 0 to week 36.
These improvements were preserved in participants who continued tirzepatide treatment through week 88 compared to those who switched to placebo.
Participants experiencing greater weight reduction and those with initial physical function limitations reported greater improvements in health-related quality of life.
Those who switched to placebo and experienced greater weight regain reported worsening of health-related quality of life.

AI simplified

OBJECTIVE: In SURMOUNT-4, participants with obesity or overweight regained substantial weight after tirzepatide withdrawal, whereas continued treatment resulted in additional weight reduction. We evaluated the effect of continued tirzepatide treatment on health-related quality of life (HRQoL) in SURMOUNT-4.

METHODS: Participants who achieved tirzepatide maximum tolerated dose (MTD; 10 or 15 mg; N = 670) during a 36-week (W) lead-in period were randomized (1:1) to continue receiving tirzepatide MTD or switch to placebo through W88. HRQoL was assessed using patient-reported outcomes (PROs: SF-36v2, IWQOL-Lite-CT, EQ-5D-5L). Post hoc analysis included changes in PROs by weight reduction categories and baseline Patient Global Impression of Status for physical activity response categories among tirzepatide-treated participants and by weight regain categories in the placebo group.

RESULTS: Tirzepatide treatment was associated with improved PROs from W0 to W36, and these improvements were maintained from W36 to W88 with continued tirzepatide treatment versus placebo. Tirzepatide-treated participants with greater weight reduction and those with physical function limitations at baseline showed numerically greater improvements in PROs. Greater weight regain among participants who switched to placebo was associated with worsening of PROs.

CONCLUSIONS: In participants with overweight or obesity, continued tirzepatide treatment was associated with maintaining HRQoL improvement, while treatment withdrawal resulted in worsening of HRQoL.

TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT04660643.

Full Text

Full text is available at the source.

View full text ↗